These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension. Lange TJ Herz; 2023 Aug; 48(4):259-265. PubMed ID: 37085727 [TBL] [Abstract][Full Text] [Related]
29. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Hoeper MM; Apitz C; Grünig E; Halank M; Ewert R; Kaemmerer H; Kabitz HJ; Kähler C; Klose H; Leuchte H; Ulrich S; Olsson KM; Distler O; Rosenkranz S; Ghofrani HA Int J Cardiol; 2018 Dec; 272S():37-45. PubMed ID: 30190158 [TBL] [Abstract][Full Text] [Related]
30. Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension. Enderle Y; Witt L; Wilkens H; Grünig E; Haefeli WE; Burhenne J J Pharm Biomed Anal; 2017 Sep; 143():291-298. PubMed ID: 28628863 [TBL] [Abstract][Full Text] [Related]
31. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis. Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265 [TBL] [Abstract][Full Text] [Related]
32. Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists. Madonna R; Cocco N; De Caterina R Cardiovasc Drugs Ther; 2015; 29(5):469-79. PubMed ID: 26145170 [TBL] [Abstract][Full Text] [Related]
33. Gender-related differences in pulmonary arterial hypertension targeted drugs administration. Marra AM; Benjamin N; Eichstaedt C; Salzano A; Arcopinto M; Gargani L; D Alto M; Argiento P; Falsetti L; Di Giosia P; Isidori AM; Ferrara F; Bossone E; Cittadini A; Grünig E Pharmacol Res; 2016 Dec; 114():103-109. PubMed ID: 27771466 [TBL] [Abstract][Full Text] [Related]
34. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639 [TBL] [Abstract][Full Text] [Related]
35. Advances in the discovery of drugs that treat pulmonary arterial hypertension. Zolty R Expert Opin Drug Discov; 2023 Apr; 18(4):445-466. PubMed ID: 37013267 [TBL] [Abstract][Full Text] [Related]
37. Management of dyspnea in advanced pulmonary arterial hypertension. Sajkov D; Petrovsky N; Palange P Curr Opin Support Palliat Care; 2010 Jun; 4(2):76-84. PubMed ID: 20407377 [TBL] [Abstract][Full Text] [Related]
38. US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies. Rucker JA; Beinfeld MT; Enright DE; Germack HD; Panjabi S; Chakinala MM; Chambers JD J Manag Care Spec Pharm; 2024 Jun; 30(6):541-548. PubMed ID: 38824632 [TBL] [Abstract][Full Text] [Related]
39. A focus on riociguat in the treatment of pulmonary arterial hypertension. Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240 [TBL] [Abstract][Full Text] [Related]
40. Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors. Kane LB; Klings ES Treat Respir Med; 2006; 5(4):271-82. PubMed ID: 16808546 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]